Malignant glioma subset from actuate 1801: Phase I/II study of 9-ING-41, GSK-3β inhibitor, monotherapy or combined with chemotherapy for refractory malignancies.

Yazmin OdiaLudimila CavalcanteHoward SafranSteven Francis PowellPamela N MunsterWen Wee MaBenedito A CarneiroBruno R BastosStacy MikrutWilliam MikrutFrancis J GilesSolmaz Sahebjam

Published in: Neuro-oncology advances (2022)

9-ING-41 plus/minus lomustine is safe and warrants further study in glioma patients.

Keyphrases

end stage renal disease
chronic kidney disease
ejection fraction
signaling pathway
randomized controlled trial
prognostic factors
peritoneal dialysis
pi k akt
locally advanced